BTG narrows focus to pharmaceuticals & medical technologies
This article was originally published in Clinica
Executive Summary
Declining revenues and rising losses at UK technology developer BTG has led CEO Louise Makin to narrow the company's remit. It will no longer seek new opportunities in the physical sciences sector but will focus on pharmaceuticals and other medical technologies, said Ms Makin, who was appointed in October 2004.